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Background: Currently few evidence based interventions are available for the prevention of PTSD within the first
weeks after trauma. Increased risk for PTSD development is associated with dysregulated fear and stress responses
prior to and shortly after trauma, as well as with a lack of perceived social support early after trauma. Oxytocin is a
potent regulator of these processes. Therefore, we propose that oxytocin may be important in reducing adverse
consequences of trauma. The ‘BONDS’ study is conducted in order to assess the efficacy of an early intervention
with intranasal oxytocin for the prevention of PTSD.
Methods/Design: In this multicenter double-blind randomized placebo-controlled trial we will recruit 220
Emergency Department patients at increased risk of PTSD. Trauma-exposed patients are screened for increased
PTSD risk with questionnaires assessing peri-traumatic distress and acute PTSD symptoms within 7 days after
trauma. Baseline PTSD symptom severity scores and neuroendocrine and psychophysiological measures will be
collected within 10 days after trauma. Participants will be randomized to 7.5 days of intranasal oxytocin (40 IU) or
placebo twice a day. Follow-up measurements at 1.5, 3 and 6 months post-trauma are collected to assess PTSD
symptom severity (the primary outcome measure). Other measures of symptoms of psychopathology, and
neuroendocrine and psychophysiological disorders are secondary outcome measures.
Discussion: We hypothesize that intranasal oxytocin administered early after trauma is an effective pharmacological
strategy to prevent PTSD in individuals at increased risk, which is both safe and easily applicable. Interindividual and
contextual factors that may influence the effects of oxytocin treatment will be considered in the analysis of the
results.
Trial registration: Netherlands Trial Registry: NTR3190.
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Given the high rates of exposure to traumatic events (70-
90%) [1-4] and a 7-8% lifetime prevalence of PTSD [1,5],
easily applicable interventions that effectively prevent
PTSD are an important public health need. Currently,
little evidence is available for effective interventions that
prevent the development of PTSD which can be adminis-
tered early after trauma exposure [6]. Single-session psy-
chological debriefing [7,8] as well as multiple sessions of
preventive Behavioral Therapy [9] administered within
3 months following traumatic events do not reduce dis-
tress, or prevent PTSD. Recently, a pilot study found that
3 sessions of prolonged exposure therapy administered
within 2 weeks after trauma reduced post-traumatic stress
reactions at 1 and 3 months post-trauma [10]. Other
secondary preventive psychological interventions, such as
brief Cognitive Behavioral Therapy (CBT), have yielded
promising results [11,12] but can be applied only several
weeks after trauma, when trauma-exposed individuals
may already have developed acute PTSD.
Pharmacologically, prolonged administration of the
beta-receptor blocking agent propranolol early after
trauma did not result in fewer PTSD symptoms [13,14].
In a small sample of participants Zohar et al. [15] re-
cently showed that a single bolus of high dose hydrocor-
tisone in trauma-exposed individuals at an Emergency
Department (ED) resulted in fewer PTSD symptoms at
2 weeks and 3 months post-trauma relative to those who
received placebo. Similarly, in another recent report of
64 traumatic injury patients it was demonstrated that
those who received a 10-day course of low dose oral
hydrocortisone started within 12 hours of the injury
reported fewer PTSD and depression symptoms at 1 and
3 months post-trauma follow-up than those who were
treated with placebo [16].
Developing interventions that target vulnerability fac-
tors associated with PTSD development is a promising
way to explore new early treatment strategies for pre-
vention [17-19] An increased risk of PTSD development
is associated with pre-existing dysregulations of (para)
sympathetic [17,18] and hypothalamic-pituitary-adrenal
axes [20,21], as well as dysregulations of central fear re-
sponses prior to [22] and shortly after trauma exposure
[23,24]. In addition, a lack of perceived social support
early after trauma is strongly related to increased PTSD
risk [25-27].
Intranasal administration of the neuropeptide oxytocin
is a candidate preventive pharmacological intervention
after trauma, since oxytocin regulates neuroendocrine,
psychophysiological and fear responses as well as socio-
emotional processes [28].
Oxytocin is synthesized in the hypothalamus from
where it is widely distributed in the brain [29]. In
addition, oxytocin is released into the bloodstream bythe pituitary gland where it acts as a hormone and stim-
ulates smooth muscle tissue contraction in e.g. child-
birth and lactation. In pioneering studies on the role of
oxytocin in social behavior, it was found to facilitate
pair-bonding and partner preference in the socially mon-
ogamous prairie vole [30,31]. Human endogenous oxyto-
cin levels increase during safe social contact [32,33], but
also during distress. Increased oxytocin activity during
distress [34,35] and its attenuating effects on HPA axis
[36] and autonomic nervous system activity [37] may in-
dicate a regulatory function of oxytocin in physiological
stress.
In humans, intranasal oxytocin administration is thought
to result in endogenous release of the hormone in a feed-
forward fashion [38]. Indeed, the recent finding that a single
intranasal administration of oxytocin (16 IU) resulted in
elevated salivary oxytocin levels up to 7 hours post-
administration while the peptide has a half time of ap-
proximately 10 minutes, supports this hypothesis [39].
Several human studies showed that intranasal oxytocin
can facilitate trust and prosocial behavior [40,41]. Fur-
thermore, intranasal oxytocin regulates responses of the
HPA axis [42] and the (para)sympathetic nervous system
[43]. In addition, intranasal oxytocin also dampened the
central fear response by lowering amygdala activity
[44-46] and potentially enhancing fear regulation by
increasing top-down control of the prefrontal cortex
over the amygdala [47].
Recently, a variety of interindividual and contextual fac-
tors that influence the effects of intranasal oxytocin have
come to light. Factors such as gender [48], attachment
style [49], and early parental experiences [50] appear to
moderate the effects of intranasal oxytocin on several
outcome measures [51,52]. These findings imply that
the effects of intranasal oxytocin need to be assessed
accounting for these potentially moderating factors.
Preclinical studies have provided support for oxytocin
treatment as a promising strategy for preventing PTSD-
like behavior. In rats, a single central oxytocin adminis-
tration either immediately or 7 days after a severe stressor
was associated with reduced PTSD-like behavior 1 week
after administration in comparison to placebo [53]. Fur-
thermore, central oxytocin administration in rats 10 mi-
nutes prior to fear conditioning did not affect fear
conditioning, but did subsequently decrease fear expres-
sion and facilitated fear extinction [54]. The same study
showed that central oxytocin administrated 10 minutes
prior to extinction training (at 1 day after fear acquisition)
inhibited fear extinction, indicating that timing of oxytocin
administration relative to traumatic memory consolidation
may be important in determining whether oxytocin pro-
motes or inhibits fear extinction. However, this finding is
not supported by the study of Cohen et al. [53], where
both treatment times (i.e. immediately after severe stress
Frijling et al. BMC Psychiatry 2014, 14:92 Page 3 of 11
http://www.biomedcentral.com/1471-244X/14/92exposure or 7 days later) showed a similar decrease in
PTSD-like behavior.
To date, no reports on the effects of intranasal oxyto-
cin in recently traumatized human individuals have been
published. One very small study showed beneficial acute
effects of intranasal oxytocin in patients who had already
developed PTSD. In 18 PTSD patients a reduction in
anxiety, restlessness, irritability and even acute PTSD
symptoms was found 50 minutes after a single dose of
oxytocin compared to placebo treatment [55].
In summary, based upon these findings and given the
well-documented vulnerability factors for PTSD devel-
opment, we propose that intranasal oxytocin applied
early after trauma may prevent the development of
PTSD, through regulating fear and stress responses and
socio-emotional processes such as perceptions of social
support [28].
Research aims and hypotheses
The primary aim of the ‘BONDS’ (Boosting Oxytocin
after trauma: Neurobiology and the Development of
Stress-related psychopathology) study is to investigate the
effectiveness of early intranasal oxytocin administration
in reducing PTSD symptoms at 1.5 month post-trauma
in trauma-exposed ED patients at increased risk of
PTSD. We expect that the oxytocin group will report
fewer PTSD symptoms at the follow-up assessment
compared to the placebo group.
As a secondary aim we will investigate whether intra-
nasal oxytocin affects PTSD severity scores at 3 and
6 months follow-up and other psychopathology symp-
toms (e.g. major depressive disorder, panic disorder,
specific phobia) and quality of life at 1.5, 3 and 6 months
follow-up.
We will also assess moderating effects of gender,
trauma type (e.g. motor vehicle accident, assault, etc.)
type, history of (childhood) trauma, coping style, attach-
ment style, and perceived social support on the main
study outcome measures. Furthermore, we will investi-
gate differences in psychophysiological, neuroendocrine,
and epigenetic measures between intervention groups at
1.5 month follow-up. We hypothesize that baseline
characteristics will moderate the effects of intranasal
oxytocin and that the experimental intervention will be
associated with more favorable outcomes on psycho-
logical, psychophysiological, neuroendocrine and epigen-
etic measures at the follow-up assessments compared to
placebo treatment.
Methods/Design
The ‘BONDS’ study is supported by the Netherlands
Organization for Health Research and Development
(ZonMw, grant no. 91210041) and by the AMC Research
Council (grant no. 110614). The study has been approvedby the Institutional Review Board of the Academic Med-
ical Center (AMC) (registration number 11/273) and is
conducted following guidelines of Good Clinical Practice
(GCP) in accordance with the principles of the Declar-
ation of Helsinki. The trial has been registered in the
Netherlands Trial Registry and can be found at http://
www.trialregister.nl (NTR3190). To assure the quality of
our study, independent quality monitoring of the trial is
performed.
Study design
The ‘BONDS’ study is a multicenter double-blind random-
ized placebo-controlled trial in recently traumatized ED
patients with increased risk of PTSD. The study design
was set up with 2 baseline assessments (T1-T2) and 4
post-intervention assessments (T3-T6) (Figure 1). Partici-
pants will be randomly assigned to 1 of the 2 intervention
groups, stratified by gender, ensuring that both genders
are equally distributed over the 2 intervention groups.
Participants
We will recruit 220 patients (males and females) be-
tween 18–65 years of age who visited 1 of the 3 partici-
pating EDs in Amsterdam (of which 2 level 1 Trauma
Centers) after a potentially traumatic event according to
the PTSD A1 criterion in the DSM-IV (i.e. event involv-
ing actual or threatened death or serious injury, or threat
to physical integrity of self or others). Only individuals
who score above the cut-off on screening questionnaires
indicating increased risk of PTSD development, speak
Dutch or English fluently and do not meet any of the
exclusion criteria (see 'List of inclusion and exclusion
criteria of the BONDS study'). are eligible to participate.
Furthermore, patients are also excluded when they are
already randomized in a currently ongoing randomized
clinical trial (RCT) conducted at the Trauma Resuscita-
tion Room of 1 of the participating Trauma Centers
(AMC) (Netherlands Trial Registry no. NTR2607).
List of inclusion and exclusion criteria of the BONDS
study:
Inclusion criteria
 Presentation at the Trauma Room or Emergency
Department after a potentially traumatic event,
according to PTSD A1 criterion in the DSM-IV
(either as a patient or direct witness)
 Trauma Screening Questionnaire (TSQ) ≥ 5 or
Peritraumatic Distress Inventory (PDI) ≥ 17,
preferably between 24 and 72 hours after trauma
exposure, but in case of contacting difficulties up to
7 days after trauma
 Age 18 – 65 years
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Figure 1 Flowchart of the BONDS study. CAPS Clinician Administered PTSD Scale; CAR cortisol awakening response; DST dexamethasone
suppression test; HRV heart rate variability; MINI MINI International Neuropsychiatric Interview; PDI Peritraumatic Distress Inventory; TSQ Trauma
Screening Questionnaire.
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 Severe or chronic systemic disease
 Current psychotic, bipolar, substance-related, severe
personality disorder, or mental retardation
 Current severe depressive disorder
 Prominent current suicidal risk or homicidal ideation
 Severe cognitive impairment or a history of organic
mental disorder
 Evidence (severe) of PTSD or depression
immediately prior to the index trauma
 History of neurological disorders (e.g., traumatic
brain injury, seizure history)
 Reports of ongoing traumatization (e.g., in case of
ongoing domestic violence)
 Evidence of clinically significant and unstable medical
conditions in which OT administration is
contra-indicative such as cardiovascular,
gastro-intestinal, pulmonary, severe renal, endocrine
or hematological disorders, glaucoma, or a stroke or
myocardial infarction within the past year
 Use of certain medication: prostaglandins, certain
anti-migraine medications (ergot alkaloids),
β-adrenergic receptor-blocking agents, and systemic
glucocorticoids.
 Sensitivity or allergy for OT or its components (e.g.,
methylhydroxybenzoate and propylhydroxybenzoate)
 Impaired consciousness, amnesia or confusion
(objectified by Glasgow Coma Scale lower than 13 at
time of inclusion) Female participants: pregnancy and breast-feeding
(NB. Female participants with childbearing potential
must have a negative pregnancy test)
Recruitment procedures
All ED patients are informed by posters and information
brochures that it is possible that they are contacted for
scientific research purposes due to their visit to the ED.
In case they do not wish to be contacted, they are able
to indicate this to the ED staff and/or researchers.
A member of the research team will identify poten-
tially trauma-exposed ED patients using the ED medical
records. Within 1 week after potential trauma exposure,
the identified individuals are contacted by telephone or
at the clinical ward to provide information about the
screening procedure (T0). After verbal consent, the
Trauma Screening Questionnaire (TSQ) [56] and Peri-
traumatic Distress Inventory (PDI) [57] are administered
to assess increased risk of PTSD development. Those
who score above the cut-off of the TSQ (5) [58] and/or
PDI (17) [59,60] and do not meet any of the exclusion
criteria receive written and verbal information about the
study and are subsequently invited to participate.
Study procedures
After verbal and written informed consent, participants will
receive a pre-intervention assessment (T1) for an extensive
check of in- and exclusion criteria and to collect baseline
characteristics (i.e. current PTSD symptoms, history of and
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questionnaires assessing psychological functioning). Only
those participants eligible for further participation will be
randomized. At home, participants will collect saliva
samples for the assessment of the cortisol awakening
curve and dexamethasone suppression test on 2 con-
secutive days. During a second appointment (T2), base-
line measures of basal psychophysiological functioning
are determined. Venous blood and saliva is collected for
the analysis of neuroendocrine and (epi)genetic mater-
ial. Subsequently, participants receive instructions on
how to use the nasal spray and will apply the first dose
in the presence of the researcher. Two weeks after the
start of the intervention, participants receive an online
questionnaire to assess psychological functioning (T3).
One month after the end of the intervention (T4) (i.e. ap-
proximately 1.5 month post-trauma) the severity of PTSD
and the presence of other psychopathology symptoms are
assessed. Additionally, blood, saliva, hair, and psychophysio-
logical measures are collected. At the remaining follow-
up sessions at 3 (T5) and 6 months (T6) after the index
trauma, the severity of PTSD and the presence of other
psychopathology symptoms will be re-assessed and a
subset of questionnaires will be re-administered.
Intervention
Participants will be blindly allocated to either intranasal oxy-
tocin (SyntocinonW, 40 IU/ml, registered in the Netherlands
as RVG 03716) or placebo (Sodiumchloride (NaCl) nasal
spray 0.8% based on the Formulary of Dutch Pharma-
cists). The bottles are re-labeled so that the oxytocin
and placebo bottles appear identical. All study medica-
tion is prepared by the hospital pharmacy of the Sloter-
vaart Hospital, Amsterdam, under Good Manufacturing
Practice (GMP) licence. Participants receive a total of
120 ml of nasal spray, divided over 3 bottles.
Participants are instructed to self-apply a total of 15
doses of 10 puffs of their allocated treatment, i.e. 40 IU
oxytocin per dose for the oxytocin condition. A dose of
40 IU twice a day is comparable to the doses previously
used in human studies investigating effects of multiple
treatments of oxytocin [61,62] and does not produce sig-
nificant side effects or adverse outcomes [63]. The first in-
tranasal dose is self-applied under researcher supervision
at the latest on day 10 post-trauma exposure (T2). The
following 14 doses will be administered in the morning
and evening of the 7 consecutive days, preferably with 12-
hour time intervals. Participants are asked to keep a medi-
cation diary to register the time of each administration
and any possible side effect or adverse event.
Screening instruments
Acute PTSD symptoms are assessed with the Trauma
Screening Questionnaire (TSQ) [56] a screening instrumentadapted from the PTSD symptom scale-self report [64].
The TSQ consists of 10 dichotomous items (5 re-
experiencing and 5 arousal items) from the DSM-IV
PTSD criteria [65] The optimal TSQ cut-off score to
predict PTSD at 1 month after trauma is 6, as was found
in a sample of trauma-exposed individuals who where
screened at 1 to 3 weeks post-trauma [58]. Since we ad-
minister the questionnaire relatively early post-trauma
(i.e. within the first week compared to 1 to 3 weeks
post-trauma) and a cut-off score of 5 still has a good
sensitivity (0.84) and specificity (0.92) [58], we use the
lower cut-off score of 5 to signal increased risk. In
addition, due to the short time period since the trauma
(i.e. preferably 3 days), we ask whether the individual
experienced the item at least once since the event (in-
stead of twice). The Dutch version has a good reliability
and validity [66]. In our own research group, we have
observed that a score of 5 or higher on the TSQ pro-
vided optimal sensitivity and specificity for PTSD diag-
nosis at 1 month post-trauma in Trauma Resuscitation
Room patients [60].
The extent of distress during and immediately after
the event is measured with the Peritraumatic Distress
Inventory (PDI) [57,67]. The PDI is an internally consist-
ent 13-item scale. Items are answered on a 5-point scale
(range: 0–52). Higher PDI scores obtained within a few
days after trauma have found to predict PTSD at
1 month post-trauma in a population of motor vehicle
casualties [59]. In our own research group, we have ob-
served that a score of 17 or higher on the PDI provided
optimal sensitivity and specificity for PTSD diagnosis at
1 month post-trauma in Trauma Resuscitation Room
patients [60].
Primary outcome measure
Diagnostic clinical interviews PTSD symptoms are
assessed with the Clinician-Administered PTSD Scale
(CAPS) [68]. The CAPS is 1 of the most widely used struc-
tured clinical interviews for diagnosing PTSD according to
DSM-IV criteria (note: at the beginning of the recruitment
phase, the DSM-5 had not yet been published). It measures
PTSD severity using the symptom clusters re-experiencing
(B-cluster, 5 symptoms), avoidance (C-cluster, 7 symptoms)
and hyperarousal (D-cluster, 5 symptoms). The CAPS dis-
tinguishes between the estimated frequency (range: 0–4)
and intensity (range: 0–4) of the various symptoms. Fre-
quency and intensity scores are added up to a total
CAPS score (range: 0–136). The Dutch version has been
validated [69].
Secondary outcome measures
Diagnostic clinical interview The MINI International
Neuropsychiatric Interview (MINI) clinical interview
[70,71] is a widely used structured clinical interview used
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orders. It is used to assess the presence of psychopath-
ology other than PTSD and lifetime PTSD. The Dutch
version has been validated [71].Self-report measures Demographics characteristics in-
cluding gender, age, social-economic status (SES), ethnic
and cultural background, medication use, medical his-
tory, smoking, nicotine, alcohol and other drug use,
sexual orientation, and relationship status are collected.
Current anxiety and depression symptoms (in the past
week) are measured with the Hospital Anxiety and
Depression Scale (HADS) [72,73], a well-established 14-
item (4-point scale) questionnaire containing 2 subscales:
HADS-A (Anxiety, 7 items, range: 0–21) and HADS-D
(Depression, 7 items; range: 0–21). Higher scores indicate
more depressive/anxious symptoms. The reliability was
high in a sample of Dutch traumatized persons [73].
Self-reported PTSD symptoms in the past week are
assessed using the Impact of Event Scale – Revised (IES-R)
[74] consisting of 22 items (5-point scale) divided in 3 sub-
scales corresponding to the 3 PTSD symptom clusters in
the DSM-IV: re-experiencing (8 items, scale range 0–32),
avoidance (8 items, range 0–32) and hyperarousal (6 items,
range 0–24). Higher scores indicate more PTSD symptoms.
The Dutch version has been validated [60].
Level of fatigue in the past 2 weeks is measured with the
Checklist Individual Strength (CIS) [75]. The CIS uses 20
items (7-point scale) divided over 4 subscales (fatigue
severity, concentration problems, reduced motivation, and
reduced activity). A total fatigue score is calculated by the
sum score of all items (range 20–140). The survey has a
good reliability and has been well validated.
Perceived health problems are assessed using a Dutch
translation of the Subjective Health Complaints inventory
(SHC) [76]. The SHC consists of 29 items on subjective
somatic and psychological complaints experienced during
the last 30 days (4 point scale: 0 (no complaints) to 3 (se-
vere complaints), range 0–87). The survey has been tested
and has satisfactory validity and reliability [76].
Quality of Life over the past 2 weeks is measured using
the brief version of the World Health Organization Quality
of Life survey (WHOQOL-BREF) [77]. The questionnaire
comprises 26 items, including 2 general items on quality of
life and 24 items covering 4 domains: physical health,
psychological health, social relationships, and environment.
The questions have 5-point Likert scales. The Dutch
WHO-QOL-BREF has good validity and reliability [78].
To assess the experience of happiness, pain, and sexual
functioning currently and over the past month, 6 ques-
tions ask for subjective feelings regarding these items on
a 10-point scale, each point accompanied by a corre-
sponding smiley face.During the psychophysiological and neuroendocrine
assessments subjective rates of acute stress are assessed
with the State and Trait Anxiety Inventory-state version
(STAI-state) [79] The STAI-state consists of 20 4-point
scale items (range 20–80) and the Dutch version has
been validated [80]. Subjective feelings of tension, anx-
iety, happiness and calmness are assessed with visual
analogue scales (VAS, scales 0–100).Self-report measures for exploratory subgroup analyses
These measures will additionally be used for exploratory
subgroup analyses of the effects of the intervention.
General subjective feelings of social support are mea-
sured with the short version of the Social Support List
(SSL-6) [81], consisting of 6 items (4-point scale) about
the amount of different types of support one receives
(range 6–24). Additionally, 6 items assess the satisfaction
with the amount of received support (range 6–24). The
list has good construct validity and high reliability [81].
Attachment style is measured using the Experiences in
Close Relationships Scale (ECR) [82] which dimensionally
measures attachment anxiety (18 items) and attachment
avoidance (18 items) (7-point Likert scale). Scores range
between 18–49 for both subscales, with higher scores indi-
cating a more anxious or avoidant attachment style. The
questionnaire has a high reliability and validity [83].
Coping strategy is measured with the Dutch Brief Coping
Strategy Indicator (DUBRISCI), a brief version of the
Coping Strategies Indicator (CSI) [84]. The question-
naire consists of 9 items (3-point scale), to assess 3 basic
modes of coping: problem solving, seeking social sup-
port, or avoiding the event (range 0–18). The CSI has
been found to be valid and reliable [84].
Peritraumatic dissociation is assessed with the Peritraumatic
Dissociation Experience Questionnaire (PDEQ) [85] and
uses 10 items of peritraumatic dissociative reactions to
a traumatic event on a 5-point scale (range 10–50). The
PDEQ is valid and reliable [86].
History of potential childhood trauma is assessed with
the short version of the Early Trauma Inventory-Self re-
port (ETI) [87]. The 27-item questionnaire assesses the
number and frequency of different types of potentially
traumatic experiences (physical, sexual, and emotional
abuse and general traumas) and has been shown to be a
valid and reliable measure of early trauma.Biological measures - Psychophysiology
Heart rate (HR) and heart rate variability (HRV) are
assessed with the Polar RS800CX (wrist watch and chest
strap). R-R intervals obtained from the equipment will
be used to calculate high-frequency HRV (HF-HRV) as
an index for parasympathetic nervous system function-
ing [88].
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Neuroendocrine measures
DHEAS and cortisol are HPA-axis indices and can be
determined in saliva. We will use Salivettes (Salivettes,
Sarstedt, Rommelsdorf, Germany) for the assessment of
DHEAS and cortisol at T2 and T4 (under resting condi-
tions). In addition, to assess normal circadian cortisol
levels and cortisol suppression by dexamethasone (DEX)
from saliva, participants are instructed to collect 5 saliva
samples per day on 2 consecutive days prior to the start
of the intervention (time points: at awakening, +15, +30,
and +60 minutes after awakening and in the evening
before going to bed). Basal cortisol levels are assessed
during the first day of saliva collection. A low dose
(0.25 mg) of dexamethasone (DEX) is administered at
11:00 pm during the first day [89], to measure cortisol
levels after suppression with DEX on the second day.
To assess retrospective cortisol levels, cortisol levels are
measured in hair [90]. Fifteen mg of hair is collected at T4.
Focus will be on the first 2 1 cm segments of scalp-nearest
samples, representing the month prior to trauma, the
month after the intervention, and a time period in between.
Saliva samples will be stored at −20°C and hair sam-
ples at room temperature until further analysis.
Oxytocin and AVP concentrations will be measured in
plasma. Blood samples are collected in 2 ice-chilled 6 ml
EDTA tubes, placed on ice immediately after sampling,
centrifuged at 4°C within 60 minutes after blood collec-
tion and stored until further analysis. Extracted plasma
will be stored at −80°C until further analysis.
(Epi)genetics
To investigate possible effects of genetic variation on the ef-
fectiveness of oxytocin treatment, we will assess carrier sta-
tus of single-nucleotide polymorphisms (SNPs) which have
previously been related to PTSD symptoms and/or dysreg-
ulated biological systems in PTSD (e.g. OXTR, glucocortic-
oid receptor, FKBP5). Furthermore, DNA methylation
of CPG-islands of these genes (i.e. epigenetics) will be
assessed. Through DNA methylation, environmental
experiences regulate gene expression, which may induce
lasting changes in stress reactivity [91,92]. Differential
levels of DNA methylation of genes related to stress
reactivity have already been associated with PTSD and
early life stress [93-95]. These measures will be used for
exploratory subgroup analyses of the effects of the inter-
vention. For the collection of (epi)genetic material 6 ml
of whole blood is collected in an EDTA tube, which is
kept at 7°C until DNA is extracted and stored by a certi-
fied laboratory.
Statistical analysis - primary outcome
To assess the efficacy of the oxytocin intervention, we
will analyze the difference in mean CAPS scores betweenthe 2 arms of the trial at 1.5 month post-trauma (T4).
Descriptive statistics will be used for exploration of the
data. All analyses will be conducted on the basis of
intention-to-treat (ITT). Results will be expressed as dif-
ferences in mean scores between the 2 groups with 95%
confidence intervals. P-values <0.05 will be considered
to indicate statistical significance.
Statistical analysis - secondary outcomes and exploratory
analyses
Additionally, we will analyze the difference in mean
CAPS scores between the 2 arms of the trial at 3 (T5)
and 6 (T6) months post-trauma. We will investigate the
difference in levels of depression and other psychopath-
ology symptoms between the 2 trial arms during the
follow-up assessments. Changes in continuous symptom
and physiological and neuroendocrine measures between
groups from pre- to post-intervention will be evaluated
by longitudinal analyses using linear mixed models. In
multivariate analyses we will investigate potential con-
founding factors, such as gender and age. Based on earl-
ier studies on early interventions to prevent PTSD [12]
and on different interindividual responses to intranasal
oxytocin administration [51,52] relevant exploratory
subgroup comparisons will be made to examine whether
treatment effects differ between specific subgroups. We
will analyze if variables such as subjective social suppo
rt, attachment, coping style, (epi)genetics, peritraumatic
dissociation, and history of childhood trauma, moderate
the effect of the intervention on our outcome measures.
Sample size calculation
Sample size calculation was based on the minimal effect
size considered to be clinically relevant in the prevention
of PTSD symptom development and on previous results
of studies on the effects of long-term oxytocin adminis-
tration in reducing psychiatric symptoms. We used the
program NQuery AdvisorW 7.0 [96] to calculate minimal
group sizes. A previous study in a similar population by
our department has shown that we can expect a stand-
ard deviation between 19.93-23.81 points on the CAPS
score at approximately 1 month after trauma [60]. Based
on a SD of 23.81, a small-to-medium effect size of d =
0.4 would result in a 9.52-point lower CAPS score in the
oxytocin-treated group compared to the placebo group
at 1 month post-intervention (a CAPS score of 45 is
required for a PTSD-diagnosis). We consider this group
difference on the CAPS to be clinically relevant.
Support for the notion that an effect size of d = 0.4
adequately reflects the potential of oxytocin to reduce
psychiatric symptoms stems from 2 previous studies on
long-term intranasal oxytocin administration in the
treatment of positive and negative symptoms in schizo-
phrenia patients [61,97]. The observed effect sizes were
Frijling et al. BMC Psychiatry 2014, 14:92 Page 8 of 11
http://www.biomedcentral.com/1471-244X/14/92between d = 0.05 - 0.88 [97] and d = 0.24 -.74 (for most
outcomes around d = 0.4) [61], depending on the outcome
measure. Noteworthy, oxytocin treatment greatly reduced
anxiety symptoms in schizophrenic patients (d = 0.62) [97].
To be able to detect a group difference with an effect
size of d = 0.4 using a two sample t-test with an alpha of
0.05 two-sided significance level and power of 80%, 100
participants per trial arm are needed. To allow for 10%
attrition (estimated from our previous study in a similar
population) we will include 110 participants in each
study group at T1. Therefore we will include 220 partici-
pants in total.
Safety and monitoring procedures of (serious) adverse
events
All adverse events reported spontaneously by the partici-
pant or observed by the research team will be recorded.
All adverse events will be judged on intensity and its
relation with the investigational product. Adverse events
will be followed until they have abated, or until a stable
situation has been reached.
All serious adverse events (SAEs; include events that
are life-threatening, require hospitalization, result in
persistent or significant disability or incapacity, are a
congenital anomaly or birth defect, or is a new event of
the trial likely to affect the safety of the participants) will
be reported to the IRB of the AMC and the competent
authority of the Netherlands, within 15 days after the
research team has first knowledge of the SAE.
SAEs that result in death or are life-threatening are
reported expedited. The expedited reporting will occur not
later than 7 days after the responsible investigator has first
knowledge of the adverse reaction. This is for a preliminary
report with another 8 days for completion of the report. If
an SAE is to occur during the nasal spray administration
period, the participant will be withdrawn from treatment.
Discussion
The ‘BONDS’ study aims to investigate the efficacy of
intranasal oxytocin administration in preventing PTSD in
trauma-exposed ED patients with increased risk of PTSD.
This is highly relevant since evidence-based interventions
that prevent PTSD in the first few weeks post-trauma are
much needed. Intranasal oxytocin is a promising pharma-
cological agent for PTSD prevention, since it acts on risk
factors associated with PTSD development, i.e. a lack of
social support and dysregulated stress and fear responses.
Based on previous early intervention studies, recruiting
ED patients for research purposes early after trauma expo-
sures is feasible [10,15,16,60,98].
Strengths and limitations
A strength of the current trial is that we assess a wide
range of variables that may moderate the effect of theOT intervention [54]. We measure a variety of relevant
contextual and interindividual factors (e.g. gender, attach-
ment style, coping and subjective social support), since it
has recently been shown that effects of oxytocin may de-
pend on these contextual and interindividual differences
[51,52]. These factors will be considered in the analysis of
the results of the ‘BONDS’ study, which allows us to deter-
mine if the intervention has diverging effects in subgroups
of participants.
In prospective studies on the development of PTSD
following a traumatic event, study populations commonly
consist of ED patients with traumatic injuries that require
hospital admission [99], since events that cause such injur-
ies immediately meet the A1 criterion of the DSM-IV for
PTSD. However, we opted for a broader recruitment strat-
egy in order to additionally identify trauma-exposed indi-
viduals with minor injuries. Although we do exclude some
trauma types (e.g. domestic violence and other ongoing
traumatizing events) we believe that our more hetero-
geneous population will yield better generalizable
results with stronger implications for general practice.
In addition, it has been reported that higher objective
injury severity scores due to a potential traumatic
event do not predict later PTSD symptoms [100].
However, due to the acute nature of the trial and the
stringent inclusion criterion of presence of increased
PTSD risk, recruiting a large of number of participants is
a challenging task. It proves to be difficult to contact all
trauma-exposed individuals in time. However, since the
BONDS study is an RCT on the efficacy of an intervention
and not an epidemiological study, it remains possible to
assess the potential effect of the intervention in the popu-
lation that we are able to include in the study.
Another possible limitation of the trial is that there is
no direct evidence that the timing we chose for the start
and duration of the intervention is the most effective. As
discussed above, preclinical studies differ in whether the
timing of the oxytocin intervention in relation to severe
stress exposure either does not influence the outcome
[53] or determines whether the intervention results in
beneficial or adverse effects [54]. In addition, starting in-
tranasal oxytocin treatments at the latest at day 10 post-
trauma is considerably later than the timing of the only
pharmacological intervention that has currently yielded
promising preventive effects, i.e. hydrocortisone within
the first 12 hours post-trauma [15,16]. Furthermore, it
may be hypothesized that intranasal oxytocin needs to
be applied prior to (i.e. not after) trauma exposure in
order to ameliorate adverse effects of traumatic stress.
However, this method may only be implemented in
high-risk populations, and requires caution and further
research, since long-term effects of multiple oxytocin
treatments over an extended time period have not been
widely studied yet. In addition, the current notion is that
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receive any form of (primary or secondary) preventive
interventions [101]. Even though pre-trauma risk factors
have been established [102], this knowledge cannot yet
be used to assess pre-trauma individual PTSD risk.
Another possible limitation of the trial is that we do
not know which dose of intranasal oxytocin is most
effective, since there is a lack of dose–response studies
of intranasal oxytocin. Only a few studies examined the
differential effects of higher (24, 40 or 48 IU) and lower
(10, 20 or 24 IU, respectively) oxytocin doses [103-105].
In these studies the dose around 20 IU (24 IU or 20 IU)
had more favorable effects compared to the other dose
studied (48, 40 or 10 IU). However, these studies were
single administration studies on non-clinical outcome
measures. We based our dose of 40 IU on 2 studies that
examined the effects of prolonged intranasal oxytocin
administration on clinical symptoms in (psychiatric) pa-
tient populations and observed favorable outcomes
[61,62]. Another limitation with regard to the dose and
administration method used is that it carries a risk of
ineffective delivery, since we apply multiple sprays per
dose [106].
In all, the ‘BONDS’ study is an RCT studying the pre-
ventive actions of intranasal oxytocin, a promising novel
early intervention aimed at modifiable risk factors of
PTSD development, in individuals exposed to trauma at
increased risk of PTSD. If effective, oxytocin administra-
tion will be an easily applicable method to reduce adverse
psychological outcome as a result of trauma exposure.
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